Clinical trials: Inflammatory
Severe Sepsis, Severe Sepsis Without Septic Shock
Sepsis Clinical Decision Support [CDS] Master Enrollment Study Protocol
This protocol will collect real-world data retrospectively from the electronic health record (EHR) as data obtained from the delivery of routine medical care to develop a machine learning (ML)-based Clinical Decision Support…
- Trial name
- NCT05304728
- Where
- 10 sites in United States
- Volunteers
- 40,000 people
- Sponsor
- Beckman Coulter, Inc.
Covid19, Sepsis
Feasibility Study of Hematology Parameters in COVID-19 Disease
The purpose of this study is to evaluate the potential for MDW and other CPD parameters (measured with CBC-DIFF) to identify COVID-19 diseased adult individuals presenting to the hospital with symptoms suggestive of COVID-19 or…
- Conditions
- Covid19, Sepsis, Adults, Emergency Department
- Trial name
- NCT04816630
- Testing
- CBC-Diff Monocyte Volume Width Distribution
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Beckman Coulter, Inc.
Chronic Inflammatory Disorder, Arthritis, Rheumatoid
A Relative Bioavailability and Food Effect Study of New Formulations
The purpose of this trial is to assess the effect of 3 formulations on the relative bioavailability of LY3009104. Participants will receive single dose of LY3009104 on 4 separate occasions with and without food.
- Trial name
- NCT01398475
- Testing
- LY3009104
- Where
- Singapore
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Ulcerative Colitis
Safety, Tolerability and Pharmacokinetics of Oral NX-13 in Healthy Adults Male and Female Volunteers
This is a randomized, double-blind, placebo-controlled, ascending dose, multi-cohort study. The study will be conducted in 2 parts: a single ascending dose (SAD) part (Part A) followed by a multiple ascending dose (MAD) part…
- Trial name
- NCT04458805
- Testing
- NX-13 250 mg
- Where
- Australia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Landos Biopharma Inc.
Crohn Disease, Colitis, Ulcerative
A Long-term Extension Study of Ustekinumab in Pediatric Participants
The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab
- Conditions
- Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
- Trial name
- UNITED (NCT05092269)
- Testing
- Ustekinumab
- Where
- 48 sites in United States, Argentina and 11 more
- Volunteers
- 159 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease, Anal Fistula
Study to Assess the Safety and Efficacy of Expanded Allogenic Adipose-derived Stem Cells (eASCs) (Cx601), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease.
The purpose of this study is to asses the safety and efficacy of adipose-derived adult stem cells from healthy donnors for treatment of complex perianal fistulas in Crohn's disease.
- Trial name
- NCT01372969
- Testing
- Cx601
- Where
- 6 sites in Spain
- Volunteers
- 24 people
- Sponsor
- Tigenix S.A.U.
Acute Lung Injury, Systemic Inflammatory Response Syndrome
Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan
The purpose of this study is to confirm the efficacy and safety of sivelestat in patients with acute lung injury associated with systemic inflammatory response syndrome.
- Trial name
- NCT00219375
- Testing
- Sivelestat sodium hydrate
- Where
- 9 sites in Japan
- Volunteers
- 649 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Crohn's Disease, IBD
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
This study (UNITI-1) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to placebo over 8 weeks, in patients with moderately to severely active Crohn's disease who have either failed or…
- Conditions
- Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
- Trial name
- NCT01369329
- Testing
- Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg
- Where
- 175 sites in United States, Australia and 21 more
- Volunteers
- 769 people
- Sponsor
- Janssen Research & Development, LLC
Perianal Fistula, Primary; Complex
Follow-up Study of Autologous Adipose-derived Stem Cells (ANTG-ASC) for the Complex Fistula (ANTG-ASC-211)
This is an open follow-up clinical trial to evaluate a sustained efficacy and safety of ANTG-ASC injection for 4 months (6 months after final dose injection) after Phase II clinical trial.
- Trial name
- ANTG (NCT01623453)
- Testing
- Autologous adipose derived stem cells(low dose group), Autologous adipose derived stem cells(high dose group)
- Where
- 2 sites in South Korea
- Volunteers
- 6 people
- Sponsor
- Anterogen Co., Ltd.
Candidiasis
Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
The purpose of the study is to evaluate the safety and efficacy of FK463 in the treatment of patients with confirmed candidemia or invasive candidiasis.
- Trial name
- NCT00036179
- Testing
- FK463
- Where
- 23 sites in Austria, France and 6 more
- Volunteers
- 75 people
- Sponsor
- Astellas Pharma Inc
Ulcerative Colitis
Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)
The purpose of this study is to evaluate the safety and efficacy of Asacol 4.8 g/day (800 mg tablet) versus Asacol 2.4 g/day (400 mg tablet
- Trial name
- ASCEND I (NCT00577473)
- Testing
- mesalamine
- Where
- 44 sites in United States
- Volunteers
- 301 people
- Sponsor
- Warner Chilcott
Crohn's Disease
Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease
The study will continue to assess the safety of certolizumab pegol (CDP870) as well as examine the evolution of long term efficacy in Crohn's disease patients who completed study C87042 [NCT00308581].
- Trial name
- Welcome2 (NCT00333788)
- Testing
- Certolizumab pegol (CDP870)
- Where
- 65 sites in United States, Austria and 10 more
- Volunteers
- 233 people
- Sponsor
- UCB Pharma
Crohn's Disease
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn's disease (CD) who are…
- Trial name
- CULTIVATE (NCT04173273)
- Testing
- Etrasimod
- Where
- 510 sites in United States, Argentina and 39 more
- Volunteers
- 379 people
- Sponsor
- Pfizer
Autoimmune Diseases, Inflammatory Diseases
Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin
The study is to assess the effect of coadministration of multiple doses of BMS-986165 on the systemic exposure of rosuvastatin in healthy participants.
- Trial name
- NCT03044873
- Testing
- BMS-986165, Rosuvastatin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Acute Kidney Injury (Nontraumatic)
Study of CXA-10 in Healthy Volunteers
This will be the first-in-human (FIH) study with CXA-10. The main purpose of this trial is to demonstrate the tolerability, safety and pharmacokinetics (PK) of CXA-10 at various incremental doses, and to demonstrate the safety…
- Trial name
- NCT02127190
- Testing
- CXA-10 emulsion
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Complexa, Inc.
Crohn's Disease
Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease
The study is designed to evaluate the clinical efficacy and safety of daily treatment for 12 weeks of oral administration of a delayed release, locally delivered 6MP (mercaptopurine) drug (80 mg), as compared to standard…
- Trial name
- NCT01094613
- Testing
- Delayed Release 6 mercaptopurine, 6 Mercaptopurine
- Where
- 11 sites in Israel
- Volunteers
- 70 people
- Sponsor
- Teva GTC
Ulcerative Colitis
Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)
The principal aim of this study is to evaluate the safety and tolerability of RO7049665 in participants with active ulcerative colitis (UC).
- Trial name
- NCT03943550
- Testing
- RO7049665
- Where
- 6 sites in United States, Georgia and 3 more
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Ulcerative Colitis (UC)
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B).
- Trial name
- NCT06619990
- Testing
- XmAb942
- Where
- 114 sites in United States, Argentina and 17 more
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Xencor, Inc.
Inflammation
To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets Under Non-Fasting Conditions
To demonstrate the relative bioavailability of Diclofenac Sodium 50 mg enteric-coated tablets under non-fasting conditions.
- Trial name
- NCT00914160
- Testing
- Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc), Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc), Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Sandoz
Catecholamine-resistant Hypotension (CRH), Distributive Shock
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
This is a Phase 3, double-blind, randomized study of LJPC-501 (angiotensin II) in adult patients diagnosed with catecholamine-resistant hypotension (CRH) conducted in multiple centers globally.
- Conditions
- Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
- Trial name
- ATHOS-3 (NCT02338843)
- Testing
- LJPC-501
- Where
- 115 sites in United States, Australia and 8 more
- Volunteers
- 344 people
- Sponsor
- La Jolla Pharmaceutical Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.